Sempre Health

Sempre Health partners with leading health plan providers and pharmaceutical companies to enhance medication adherence and decrease out-of-pocket costs for patients. Through an approach that combines technology, behavioral science, dynamic pricing, and incentive alignment, Sempre Health encourages patients to make responsible health decisions, which in turn generates cost savings for insurers, care providers, and pharmaceutical companies. This model allows patients to benefit financially from their adherence to prescribed medication regimens, effectively improving health outcomes and making medications more affordable.

Key customers and partnerships

Sempre Health works directly with health plan providers and pharmaceutical companies to improve medication adherence and reduce out-of-pocket costs for patients. These benefits are extended to the consumers, who are the patients using prescribed medications. As of April 2019, Sempre Health had over 125,000 patients enrolled in its program and was on track to surpass 250,000 patients on the platform by the end of 2020.

In November 2023, Sempre Health partnered with Organon, a global healthcare company, to launch an adherence program that aimed to motivate patients to adhere to prescriptions through a system of discounts based on timely refills. The program targets various factors contributing to non-adherence by incorporating elements like Sempre's auto-refill technology and personalized text messages.

Funding and financials

In September 2023, Sempre Health raised USD 20 million in additional funding. The funding round saw participation from three new investors, including Cencora Ventures and Echo Health Ventures, as well as existing investors such as Blue Venture Fund, UPMC Enterprises, and Industry Ventures. Sempre Health planned to use the new funding to speed up the expansion of its network of pharmaceutical manufacturers and health plan providers. With an outlook to expand into adjacent product areas, the company also aimed to significantly grow the number of patients benefiting from its solution.